SCHEMBL2735701

SCHEMBL2735701

Cc1ccc(S(=O)(=O)N(c2cc(Cl)c(C)cc2OCc2ccc(C(=O)O)cc2C)C(C)C)o1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.40
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
PTGER1 P34995 2/20 0.34
NPC1 O15118 1/20 0.34
SRD5A2 P31213 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
KDM6B O15054 1/20 0.34
KDM4A O75164 1/20 0.34
KDM4B O94953 1/20 0.34
KDM5A P29375 1/20 0.34
KDM4D Q6B0I6 1/20 0.34
KDM2B Q8NHM5 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213449 0.93 HDAC8 (0.41) MRGPRX4ALDH1A1MEN1KMT2AKDM4A
SCHEMBL213787 0.93 MRGPRX4 (0.36) MRGPRX4ALDH1A1MAPTMEN1KMT2A
SCHEMBL213258 0.92 MRGPRX4 (0.40) MRGPRX4PTGER1NPC1SRD5A2KDM4A
SCHEMBL216079 0.91 MRGPRX4 (0.40) MRGPRX4PTGER1NPC1SRD5A2KDM4A
SCHEMBL214369 0.90 HDAC8 (0.41) MRGPRX4ALDH1A1MEN1KMT2AKDM4A
SCHEMBL216660 0.89 MCL1 (0.39) MRGPRX4ALDH1A1MAPTPKMMEN1
SCHEMBL214566 0.88 MRGPRX4 (0.35) MRGPRX4KDM4E
SCHEMBL214321 0.87 RXRA (0.35) MRGPRX4PTGER1NPC1
SCHEMBL213190 0.86 KDM5A (0.37) MRGPRX4KDM4AKDM5AKDM2BKDM4C
SCHEMBL214364 0.85 MCL1 (0.39) MRGPRX4ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088802-B2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation ONO PHARMACEUTICAL CO., LTD. (JP) 2012-01-03 US disclosed
US-8088802-B2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation ONO PHARMACEUTICAL CO., LTD. (JP) 2012-01-03 US disclosed
US-20100041708-A1 N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-18 US disclosed
US-20100041708-A1 N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-18 US disclosed
US-7629369-B2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation ONO PHARMACEUTICALS CO., LTD. (JP) 2009-12-08 US disclosed
US-7629369-B2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation ONO PHARMACEUTICALS CO., LTD. (JP) 2009-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041708-A1 N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION PTGER1, PTGER2, PTGES MRGPRX4 747/4885ALDH1A1 1239/4885MAPT 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.